Update on the treatment of post-menopausal osteoporosis

British Medical Bulletin

Volumn 86, Issue 1, 2008, Pages 129-143

  Cole, Zoë ^a   Dennison, Elaine ^a   Cooper, Cyrus ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Fracture; Osteoporosis; Prevention; Risk; Treatment

Indexed keywords

ALENDRONIC ACID; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM ANTAGONIST; CALCIUM SENSING RECEPTOR ANTAGONIST; CATHEPSIN K INHIBITOR; COLECALCIFEROL; DENOSUMAB; DROLOXIFENE; IBANDRONIC ACID; INTEGRIN ANTAGONIST; LASOFOXIFENE; OSPEMIFENE; PARATHYROID HORMONE[1-34]; PLACEBO; PROTEIN INHIBITOR; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SCLEROSTIN BLOCKING AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE MASS; BONE NECROSIS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRESS SYNDROME; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP FRACTURE; HUMAN; HYPERSENSITIVITY REACTION; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TREATMENT CONTRAINDICATION; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 44949086638     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldn017     Document Type: Review

References (32)

1. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990, 85, 456-461.
2. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10, 1478-1487.
3. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348, 1535-1541.
4. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280, 2077-2082.
5. Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350, 1189-1199.
6. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000, 12, 1-12.
7. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282, 1344-1352.
8. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11, 83-91.
9. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344, 333-340.
10. Harrington JT, Ste-Marie LG, Brandi ML et al. Risedronate rapidly reduces the risk for non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 74, 129-135.
11. Chesnut CH III, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19, 1241-1249.
12. Miller PD, McClung MR, Macovei L et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005, 20, 1315-1322.
13. Delmas PD, Adami S, Strugala C et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006, 54, 1838-1846.
14. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356, 1809-1822.
15. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357, 1799-1809.
16. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296, 2927-2938.
17. Marie PJ, Hott M, Modrowski D et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993, 8, 607-615.
18. Nielsen SP, Slosman D, Sorensen OH et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 1999, 2, 371-379.
19. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350, 459-468.
20. Reginster JY, Seeman E, de Vernejoul MC et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005, 90, 2816-2822.
21. Seeman E, Vellas B, Benhamou C et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006, 21, 1113-1120.
22. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344, 1434-1441.
23. Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146, 326-339.
24. Chesnut CH III, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109, 267-276.
25. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J 1994, 308, 1081-1082.
26. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354, 669-683.
27. Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005, 365, 1621-1628.
28. O'Loughlin JL, Robitaille Y, Boivin JF, Suissa S. Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol 1993, 137, 342-354.
29. Kiel DP, Magaziner J, Zimmerman S et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 2007, 298, 413-422.
30. Martyn-St JM, Carroll S. High-intensity resistance training and postmenopausal bone loss: a meta-analysis. Osteoporos Int 2006, 17, 1225-1240.
31. McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354, 821-831.
32. Kanis JA, Burlet N, Cooper C et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19, 399-428.